Benzinga
Benzinga
Benzinga
domenica, settembre 13

Regeneron Pharmaceuticals Inc

REGNNASDAQ
Trade with Public
Trade with Public
$781.49
-11.77-1.48%
In chiusura: Sep 11, 5:00 PM EST
$781.49
N/A
Post-mercato: Sep 11, 4:33 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoDividendiConfrontaOpzioniRapporto azionario

Regeneron Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Regeneron Pharmaceuticals (REGN).

Price Target Range — 6 Quarters

Analyst Consensus — 23 Analysts

17Buy
6Hold
Consensus RatingBuy# Analysts23Avg. Consensus PT$798Upside to Avg. PT+2.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Sep 10, 2026HSBCRajesh KumarPT RaiseBuy$800→$920
Aug 17, 2026Leerink PartnersDavid RisingerPT RaiseMarket Perform$641→$824
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.
Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $740

Citigroup analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $700 to $740.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030

Guggenheim analyst Brad Canino maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $1000 to $1030.
Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $737

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $696 to $737.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $758

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $730 to $758.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $795

Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $750 to $795.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved